Breakthrough Discovery: Ozempic Slashes Knee Osteoarthritis Pain by a Staggering 50% – New Study Reveals
Clinical trial results published this week showed that the active ingredients in diabetes and weight-loss drugs Ozempic and Wegovy were associated with nearly halving reported pain in patients with knee osteoarthritis and obesity.
that Research funded by Novo NordiskThe makers of Ozempic and Wegovy had 407 participants take either the active ingredient semaglutide or a placebo for 68 weeks. Approximately 82% of participants were women.
To measure pain, researchers used the Western Ontario and McMaster Universities Arthritis Index (WOMAC). The WOMAC involves participants assessing pain, difficulty, and physical function when doing daily activities such as going up and down stairs or sitting.
Participants’ average WOMAC pain score at the start of the trial was 70.9. By week 68, those taking semaglutide reported an average WOMAC pain score of 29.2, while those taking placebo reported an average pain score of 43.4.
Semaglutide participants lost an average of 13.7% of their weight, while those taking the placebo lost an average of 3.2%.
“Among patients with obesity and knee osteoarthritis with moderate to severe pain, once-weekly injectable semaglutide treatment resulted in significantly greater reductions in body weight and knee osteoarthritis-related pain compared to placebo,” the study found. The conclusion was stated.
as follows: Johns Hopkins Arthritis Center NotesOverweight women have nearly four times the risk of developing knee osteoarthritis compared to non-obese women. For obese men, the risk is five times higher than for non-obese men.
GLP-1 agonists such as semaglutide have been studied. Uses other than obesity and diabetes. Semaglutide has been studied for its potential benefits in treating addiction, kidney failure, liver disease, and early Alzheimer’s disease.